Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Ad hoc announcement pursuant to Art. 53 LR

Novartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged.

Basel, July 20, 2021 — Novartis and the Novartis US Foundation today announced a planned 10-year collaboration with Coursera, the National Medical Association, Thurgood Marshall College Fund, Morehouse School of Medicine and 26 additional Historically Black Colleges, Universities and Medical Schools (HBCUs) to co-create programs that address the root causes of systemic disparities in health outcomes and create greater diversity, equity and inclusion across the research and development ecosystem.

Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity

AbbVie

Eli Lilly

Among members of Big Pharma, Novartis AG ( NVS , Financial) brought the most novel medicines to market in the past five years, according to a report from Evaluate Vantage.

Novartis, Eli Lilly and AbbVie Top 5-Year New Drug Productivity List

Biogen

Pfizer

uniQure

Roche Holding AG

SAGE Therapeutics

Several drugmakers have important clinical trial updates on the way.

Late-Stage Clinical Study Readouts Biotech Investors Should Watch

Molecular Partners AG (NASDAQ: MOLN) reported on the clinical progress of its antiviral candidate, ensovibep, as part of a presentation with its partner Novartis AG (NYSE: NVS) at the Credit Suisse ESG Forum Switzerland virtual event.  Ensovibep is currently being studied in Phase 2 single-arm pilot study in ambulatory patients in the Netherlands; a global Phase 2/3 study in ambulatory patients, in collaboration with Novartis (EMPATHY); and a National Institutes of Health-sponsored global Phase 3 study in hospitalized patients as part of the ACTIV-3 master protocol.

Molecular Partners - Novartis' COVID-19 Antiviral Shows Encouraging Preclinical Action Against Delta Variant

British American Tobacco

Cardinal Health

Chevron

Imperial Brands PLC

Realty Income Corp

Red Electrica Corp SA

Sanofi

Swiss Re AG

AT&T

Unilever

Exxon Mobil

Kiplinger "insights for investors" online, first listed 91 "Top Dividend Stocks From Around The World" 7/13/20. Two recent Kiplinger articles provided 102 Top Dividend Stocks on Earth as of 7/1/21. 39 European “Dividend Aristocrats,” show 10 years of stable or increasing dividends; 65 S&P 500 Aristocrats show 25 years of increases for U.S. companies.

102 'Top Dividend Stocks On Earth' July Update

Novartis AG (NYSE: NVS) could get into the field of messenger ribonucleic acid (mRNA) technology, reported Reuters, citing Chairman Joerg Reinhardt in a newspaper interview. In the Aargauer Zeitung interview, Reinhardt also highlighted the company's interest in anti-infective products that the pandemic has also driven.

Novartis Looks To Enter mRNA Technology, Says Chairman: Reuters

Novartis AG (NYSE: NVS) said it dutifully paid millions to Genentech as part of a patent licensing deal dated back to 2005.  But now, Novartis discovered it accidentally overpaid by nearly $210 million to Roche Holding AG's (OTC: RHHBY) unit.

Novartis Claims It Overpaid Genentech $210M In Patent Licensing Pact

Novartis wants Roche to return $210 million after accusing its Swiss rival of inappropriately pocketing fees from a 16-year-old patent licensing agreement, according to a U.S. District Court lawsuit.

Novartis fights Roche in $210 million U.S. dispute over licensing fees

Abbott Labs

Some might be surprised to see income-paying stocks among the ARK Invest founder's high-growth picks.

These 3 High-Dividend Stocks Have Cathie Wood's Seal of Approval

Basel, June 28, 2021 — Novartis announced today the appointment of Rob Kowalski, Pharm.D., Global Head Regulatory Affairs and US Head of Drug Development as Chief People & Organization Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis (ECN), effective September 1, 2021.

Novartis appoints Rob Kowalski as Chief People & Organization Officer

Novartis AG (NYSE: NVS) announced new data from the completed two-copy cohort of Phase 3 SPR1NT trial of Zolgensma (onasemnogene abeparvovec), gene therapy for spinal muscular atrophy (SMA). The data were presented at the European Academy for Neurology Virtual Congress 2021.

Novartis Touts More Positive Zolgensma Data In Spinal Muscular Atrophy Patients

The CEO of Swiss pharmaceutical giant Novartis on Wednesday outlined how policymakers and the healthcare industry can improve pandemic preparedness.

Novartis CEO says future pandemics are bound to happen. Here's how to prepare for the next one

Coca-Cola

Of the equities that make up the S&P 500, only seven have market caps larger than $200 billion and pay a dividend yield of at least 3%.

4 Buy-Rated Giants Pay a Dividend of at Least 3%

Basel, June 11, 2021 — Novartis today announced new Phase II data for iptacopan (LNP023), an investigational oral treatment for paroxysmal nocturnal hemoglobinuria (PNH), presented at the 26th Annual Congress of the European Hematology Association (EHA). In the study (NCT03896152), treatment with 12 weeks of iptacopan monotherapy was generally well tolerated with no unexpected safety findings and resulted in rapid and durable transfusion-free improvement of hemoglobin levels in the majority of patients1.

Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria

Novartis plans to close a plant in the southern Swiss town of Locarno, the drugmaker said on Wednesday, citing falling demand for testing products.

Novartis to close Swiss plant, 50 jobs to go

Amcor Plc

Enbridge

Dividend aristocrats have proven to be one of the best ways to retire rich over time. But today they are 30% overvalued. Foreign dividend blue chips are 19% overvalued, including global aristocrats. But something great is always on sale if you have the right watchlist.

3 Best Global Dividend Aristocrats You Can Safely Buy Today

Novartis' (NVS) rare kidney disease candidate meets its primary goal in a phase II study.

Novartis (NVS) Posts Positive Data on Kidney Disease Candidate

Novartis AG (NYSE: NVS) announced data from Phase 2 trial evaluating iptacopan (LNP023) in rare kidney disease IgA nephropathy (IgAN). Data were presented at the 58th ERA-EDTA Congress.

Novartis's Iptacopan Aces Mid-Stage Kidney Disease Trial

Basel, June 0 6 , 20 2 1 — Novartis today announced Phase II primary endpoint data showing investigational iptacopan (LNP023) – a first-in-class, oral, targeted factor B inhibitor – reduced protein in the urine (proteinuria), an increasingly recognized surrogate marker correlating with progression to kidney failure2, and showed promise in stabilizing kidney function in patients with IgA nephropathy (IgAN)1. The data were presented at the 58th ERA-EDTA Congress held virtually from June 5–8, 2021.

Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)

Novartis AG (NYSE: NVS) reported the final analysis from the NETTER-1 phase 3 study comparing Lutathera plus 30 mg Sandostatin LAR (octreotide) to 60 mg octreotide LAR in patients with midgut neuroendocrine tumors. Lutathera failed to significantly prolong the lives of patients with midgut neuroendocrine tumors, according to data unveiled at the American Society of Clinical Oncology.

Novartis' Neuroendocrine Tumors Targeted Radiotherapy Takes Small Hit on Clinically Relevant Overall Survival

Novartis (NVS) posts results from a late-stage study on radioligand therapy at the 2021 ASCO.

Novartis (NVS) Announces Data on Radioligand Therapy at ASCO

Basel, June 4, 2021 — Novartis today announced the first published mature overall survival (OS) and updated overall response rate (ORR) data following treatment with Tabrecta® (capmatinib) in adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14)1-3. Data from the ongoing, pivotal, multi-cohort Phase II GEOMETRY mono-1 study will be presented today during the 2021 Annual American Society of Clinical Oncology (ASCO) Virtual Scientific Meeting (Poster Discussion Session, Lung Cancer—Non-Small Cell Metastatic; June 4, 2021, 9:00 AM-10:00 AM CT; abstract 9020).

Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

Basel, June 4, 2021 — Novartis announced today results from the pivotal Phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor tislelizumab improved overall survival (OS) versus chemotherapy (median 8.6 months vs. 6.3 months, p=0.0001).1 The study evaluated tislelizumab in patients with unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) who had received prior systemic therapy. Results were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

Novartis AG (NYSE: NVS) has announced results from Phase 3 VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus best standard of care (SOC) in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). Novartis said it would file for approval for the drug, known as Lu-PSMA-617, in the US and Europe in the second half of 2021 while pushing forward with pivotal studies on earlier-stage patients.

Novartis' Prostate Cancer Radioligand Therapy Extended Overall Survival by Four Months

News for Novartis Stock (NVS)